Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.570
Neutral
RSI(14)
50.239
Neutral
STOCH(KDJ)(9,3,3)
77.607
Buy
ATR(14)
12.254
Low Volatility
CCI(14)
65.081
Neutral
Williams %R
59.506
Sell
TRIX(12,20)
-0.342
Sell
StochRSI(14)
91.845
Overbought
Search
Alnylam Pharmaceuticals Inc
ALNYAdd to Watchlist
205.420USD
-81.200-28.33%
Close 07-29 16:00（ET）Quotes delayed by 15 min
27.19BMarket Cap
50.28P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-28.33%
5 Days
-23.06%
1 Month
-30.01%
6 Months
-40.77%
Year to Date
-48.34%
1 Year
-37.86%
Key Figures
224.000Open
230.000High
9.75MVolume
50.28P/E TTM
18.04P/E Dynamic
--Dividend TTM
7.37%Turnover Ratio
286.620Prev. Close
197.810Low
1.33BTurnover
LossP/E Static
34.46P/B
0.00%Div Yield TTM
11.52%ROA
495.55052wk High
7.57Volume Ratio
-278.16MNet Profit
132.38MShares
4.0857EPS TTM
0.29Beta
90.36%ROE
284.28052wk Low
11.23%Amplitude
74.54%Gross Margin
27.19BMarket Cap
-2.10Reward/Risk
2.37%Risk Rate
TradingKey Stock Score of Alnylam Pharmaceuticals Inc
Currency: USD Updated: 2026-07-29Key Insights
Alnylam Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 21 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 440.59.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alnylam Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Alnylam Pharmaceuticals Inc Highlights
StrengthsRisks
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 103.14% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 70.15, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 133.66M shares, decreasing 4.33% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 119.30K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.46.
Analyst Rating
Based on
30
analysts
Buy
Current Rating
440.590
Target Price
+58.26%
Upside Space
Alnylam Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
30
analysts
Buy
Current Rating
440.590
Target Price
+58.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Alnylam Pharmaceuticals Inc
ALNY
30
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
278.788
Sell
MA10
275.559
Sell
MA20
289.409
Sell
MA50
291.519
Sell
MA100
302.191
Sell
MA200
351.862
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alnylam Pharmaceuticals Inc Info
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Ticker SymbolALNY
CompanyAlnylam Pharmaceuticals Inc
CEOGreenstreet (Yvonne L)
Websitehttps://www.alnylam.com/
Shareholders
Related Instruments
-4.49%
-3.63%
-1.11%
-2.15%
-0.44%
-0.26%
+0.03%
0.00%
-1.11%
-0.97%
+2.81%
-0.34%
-2.15%
-2.56%
-4.39%
+6.12%
0.00%
-1.09%
-2.76%
-0.88%Popular Instruments
52281.700
+723.700 (+1.40%)
28207.000
+1093.200 (+4.03%)
7452.600
+149.800 (+2.05%)
14854.000
+168.000 (+1.14%)
63633.000
+2704.000 (+4.44%)
6371.800
+151.300 (+2.43%)
83.380
-0.561 (-0.67%)
333.310
-4.880 (-1.44%)
195.150
+5.140 (+2.71%)
4108.090
+40.950 (+1.01%)
FAQs
What is the current price of Alnylam Pharmaceuticals Inc (ALNY)?
The current price of Alnylam Pharmaceuticals Inc (ALNY) is 287.19.
What is the symbol of Alnylam Pharmaceuticals Inc?
The ticker symbol of Alnylam Pharmaceuticals Inc is ALNY.
What is the 52-week high of Alnylam Pharmaceuticals Inc?
The 52-week high of Alnylam Pharmaceuticals Inc is 495.55.
What is the 52-week low of Alnylam Pharmaceuticals Inc?
The 52-week low of Alnylam Pharmaceuticals Inc is 284.28.
What is the market capitalization of Alnylam Pharmaceuticals Inc?
The market capitalization of Alnylam Pharmaceuticals Inc is 38.02B.
Is Alnylam Pharmaceuticals Inc (ALNY) currently rated as Buy, Hold, or Sell?
According to analysts, Alnylam Pharmaceuticals Inc (ALNY) has an overall rating of Buy, with a price target of 440.59.
What is the Earnings Per Share (EPS TTM) of Alnylam Pharmaceuticals Inc (ALNY)?
The Earnings Per Share (EPS TTM) of Alnylam Pharmaceuticals Inc (ALNY) is 2.39.